Click to follow
Therapeutic Antibodies, a bio-babe that suffered the indignity of a difficult stock market birth, gained 27p to 484p as Dr Erling Refsum, the pharmaceutical analyst at Yamaichi, said the shares were "still suffering from some post-float indigestion which makes for a good buying time". He believes the sales potential is high for what are low-risk projects. Because of an unenthusiastic reception the drug developer was forced to cut its value from pounds 150m to pounds 112m to get the issue away. The shares were sold at 525p. There is a suggestion a well-known pharmaceutical personality is about to join the board.

Shell company CRP Leisure continues to seek acquisitions. It currently has one trading asset, theatrical designer Victor Mara. Shares are 2.25p.